Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20:13:1020003.
doi: 10.3389/fimmu.2022.1020003. eCollection 2022.

Immunotherapeutic progress and application of bispecific antibody in cancer

Jingyue Kang  1   2 , Tonglin Sun  1   3 , Yan Zhang  1   3
Affiliations
Review

Immunotherapeutic progress and application of bispecific antibody in cancer

Jingyue Kang et al. Front Immunol. .

Abstract

Bispecific antibodies (bsAbs) are artificial antibodies with two distinct antigen-binding sites that can bind to different antigens or different epitopes on the same antigen. Based on a variety of technology platforms currently developed, bsAbs can exhibit different formats and mechanisms of action. The upgrading of antibody technology has promoted the development of bsAbs, which has been effectively used in the treatment of tumors. So far, 7 bsAbs have been approved for marketing in the world, and more than 200 bsAbs are in clinical and preclinical research stages. Here, we summarize the development process of bsAbs, application in tumor treatment and look forward to the challenges in future development.

Keywords: antibody constructs; bispecific antibody; bsAb; clinical trials; tumor immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Structures of bsAbs.
Figure 2
Figure 2
Triomab antibodies redirect T cells and other accessory cells to a tumor cell.
Figure 3
Figure 3
BiTE antibodies redirect T cells to a tumor cell.
Figure 4
Figure 4
Examples of obligate mechanisms of action of bsAbs. (A) Linking T cells and tumor cells. (B) Receptor inhibition. (C) Receptor activation. (D) Analoging cofactor. (E) Using target to transport. (F) Surrogate cytokine agonists.
Figure 5
Figure 5
The future directions of bsAbs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys (1961) 93(2):460–2. doi: 10.1016/0003-9861(61)90296-X - DOI - PubMed
    1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnol (Reading Mass) (1992) 24:524–6. doi: 10.1038/256495a0 - DOI - PubMed
    1. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature (1985) 316(6026):354–6. doi: 10.1038/316354a0 - DOI - PubMed
    1. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature (1985) 314(6012):628–31. doi: 10.1038/314628a0 - DOI - PubMed
    1. Linke R, Klein A, Seimetz D. Catumaxomab: Clinical development and future directions. Mabs (2010) 2(2):129–36. doi: 10.4161/mabs.2.2.11221 - DOI - PMC - PubMed

Publication types

Substances